Alpha 2.0
Login Register
» Authors » Terje R Pedersen

Terje R Pedersen

Explore the profile of Terje R Pedersen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 127
Citations 13597
Followers 0
Related Specialties
Cardiology & Vascular Diseases
General Medicine
Rheumatology
Top 10 Co-Authors
Marc S Sabatine
Robert P Giugliano
Ingar Holme
Peter S Sever
John J P Kastelein
Anders G Olsson
Anthony C Keech
Matti J Tikkanen
Sabina A Murphy
Ole Faergeman
Published In
Am J Cardiol
Circulation
J Am Coll Cardiol
JAMA Cardiol
Lancet
Affiliations
Soon will be listed here.
Recent Articles
1.
LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial
Sever P, Gouni-Berthold I, Keech A, Giugliano R, Pedersen T, Im K, et al.
Eur J Prev Cardiol . 2021 Jul; 28(8):805-812. PMID: 34298555
Aims: Some trials have reported diminished efficacy for statins in the elderly, and in women compared with men. We examined the efficacy and safety of evolocumab by patient age and...
2.
Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects　- A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial
Keech A, Oyama K, Sever P, Tang M, Murphy S, Hirayama A, et al.
Circ J . 2021 May; 85(11):2063-2070. PMID: 33980763
Background: There are concerns that Asian patients respond differently to some medications. This study evaluated the efficacy and safety of evolocumab among Asian vs. other subjects in the FOURIER trial,...
3.
Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project
Landmesser U, Pirillo A, Farnier M, Jukema J, Laufs U, Mach F, et al.
Atheroscler Suppl . 2021 Feb; 42:e49-e58. PMID: 33589224
Background And Aims: Post-acute coronary syndrome (ACS) patients are at very high risk for recurrent events and mortality, despite the availability of effective pharmacological approaches. Aim of this survey was...
4.
LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial
Vallejo-Vaz A, Packard C, Ference B, Santos R, Kastelein J, Stein E, et al.
Atherosclerosis . 2021 Jan; 320:1-9. PMID: 33497862
Background And Aims: Trial evidence for the benefits of cholesterol-lowering is limited for familial hypercholesterolemia (FH) patients, since they have not been the focus of large outcome trials. We assess...
5.
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial
Deedwania P, Murphy S, Scheen A, Badariene J, Lira Pineda A, Honarpour N, et al.
JAMA Cardiol . 2020 Aug; 6(2):139-147. PMID: 32785614
Importance: The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER randomized clinical trial. Patients with metabolic syndrome (MetS) are at increased cardiovascular risk. Objective: To...
6.
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial
Gencer B, Mach F, Murphy S, De Ferrari G, Huber K, Lewis B, et al.
JAMA Cardiol . 2020 May; 5(8):952-957. PMID: 32432684
Importance: The 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol identified patients with recent (past 12 months) myocardial infarction (MI) as very high...
7.
An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial
Bergmark B, ODonoghue M, Murphy S, Kuder J, Ezhov M, Ceska R, et al.
JAMA Cardiol . 2020 Apr; 5(6):709-713. PMID: 32347887
Importance: Despite recent advances in treatment of severe aortic valve stenosis (AS), AS remains a life-threatening condition with no proven disease-modifying therapy. Low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) have...
8.
Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial
Wiviott S, Giugliano R, Morrow D, De Ferrari G, Lewis B, Huber K, et al.
JAMA Cardiol . 2020 Apr; 5(7):787-793. PMID: 32347885
Importance: The PCSK9 inhibitor evolocumab reduced major vascular events in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial, yet the types and sizes...
9.
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis
Giugliano R, Pedersen T, Saver J, Sever P, Keech A, Bohula E, et al.
Stroke . 2020 Apr; 51(5):1546-1554. PMID: 32312223
Background and Purpose- The PCSK9 (proprotein convertase subtilisin-kexin type 9) monoclonal antibody evolocumab lowered LDL (low-density lipoprotein) cholesterol by 59% to 0.8 (0.5-1.2) mmol/L and significantly reduced major vascular events...
10.
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
Marston N, Gurmu Y, Melloni G, Bonaca M, Gencer B, Sever P, et al.
Circulation . 2020 Apr; 141(20):1600-1607. PMID: 32223429
Background: The relationship between cholesterol levels and risk of venous thromboembolism (VTE) is uncertain. We set out to determine the effect of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition on...